PARSIPPANY, NJ & KING OF PRUSSIA, PA — Ferring Pharmaceuticals has teamed up with SK pharmteco to scale up the commercial manufacturing capacity of ADSTILADRIN (nadofaragene firadenovec-vncg), a gene therapy approved by the FDA in December 2022. This partnership aims to ensure a stable, long-term supply of the drug, addressing the needs of adult patients battling high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC).
SK pharmteco, a contract development manufacturing organization (CDMO), will be tasked with manufacturing, testing, and releasing the drug substance pending U.S. Food and Drug Administration (FDA) approval. This collaboration marks a significant step towards diversifying the production of ADSTILADRIN, which Ferring projects will see increased commercial demand.
The importance of this partnership extends beyond immediate supply concerns. With bladder cancer now ranked as the ninth most common cancer globally, and the seventh in the United States—primarily presenting as NMIBC—the demand for effective treatments like ADSTILADRIN is on the rise. Ferring’s proactive approach to expand its manufacturing capabilities, both through external partnerships and within its own facilities in Finland and New Jersey, underscores a commitment to meet this growing need.
Bipin Dalmia, Global Head of Uro-Oncology Franchise at Ferring Pharmaceuticals, emphasized the significance of ensuring a stable supply for an emerging field like gene therapy, highlighting the goal to fulfill an unmet clinical need for patients. Similarly, SK pharmteco’s CEO, Joerg Ahlgrimm, expressed pride in supporting the manufacture of ADSTILADRIN, aligning with their mission to accelerate the delivery of life-saving therapies worldwide.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.